NMC again threatens action against medical colleges not paying stipend
National Medical Commission (NMC) has yet again issued a public notice threatening to take action against medical colleges that do not pay stipends to interns and resident doctors.
With no evidence of any action being taken after similar threats in 2023 and 2024, it remains to be seen whether change in chairman of the commission leads to action this time.
Three months back, NMC had threatened to impose Rs 50,000 as penalty on medical colleges which save several crores of rupees every year by not paying stipend. NMC's regulations stipulate that all medical colleges have to pay interns and resident doctors stipend equivalent to what state govt medical colleges are paying.
Just three days before the latest public notice dated July 11, NMC had issued another notice shifting the responsibility of addressing grievances of medical students to medical colleges, universities and directorates of medical education of the respective states. Yet, it is now threatening to take action including imposition of financial penalties, withdrawal of course recognition and suspension of admissions.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Young Woman Lives in a Shed, Slams Viewers With The Interior
Tips and Tricks
Undo
The latest notice reminded medical colleges that, in keeping with SC order of April 29, all private and deemed universities must disclose detailed information regarding tuition fees, hostel charges, caution deposits and all miscellaneous charges at pre-counselling stage. Citing another order of SC in 2022 and the commission's own regulations, it said payment of stipend was mandatory.
NMC threatened that non-compliance would attract action under Establishment of Medical Institutions, Assessment and Rating Regulations, 2023, Maintenance of Standards of Medical Education Regulations, 2023, and Post Graduate Medical Education Regulations, 2023.
It added that these measures to ensure payment of stipend and for disclosure of various kinds of fees well before counselling were 'a part of NMC's commitment to fostering fair, ethical and transparent practices in medical education across the country'.
In April 2023, NMC did a survey among medical college students on stipend being paid to them. An RTI query to NMC revealed the survey showed that over 60 colleges were not paying stipend, while about 50 were paying less than Rs 5,000 a month.
In Aug 2023, NMC issued 'an advisory' to all colleges regarding payment of stipend. With SC cracking down on NMC regarding non-payment of stipend, in Nov 2024, the commission issued show cause notices to 198 medical colleges for failing to submit stipend payment data.
NMC has written to colleges threatening 'strict action' in Aug 2023, Nov 2024 and now on July 11, 2025. Yet, there is no record of any action being taken against any college for non-payment of stipend till now.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
30 minutes ago
- Business Standard
Cipla Q1 net profit up 10%, driven by consumer health and generics
Pharma major Cipla posted a 10 per cent year-on-year increase in its consolidated net profit, reaching Rs 1,297 crore in the first quarter of financial year 2026 (Q1FY26), up from Rs 1,177 crore. Revenue from operations also rose by 3.2 per cent YoY, reaching Rs 6,837 crore compared to Rs 6,672 crore last year. The increase in profit and revenue was attributed to robust performance in the consumer healthcare and generic markets. Sequentially, revenue was up by 3.6 per cent, with net profit increasing by 6.2 per cent. The results were announced during market hours. Cipla's stock rose by 2.95 per cent, ending the day's trade at Rs 1,531.10 on the BSE. Umang Vohra, Managing Director and Global Chief Executive Officer of Cipla, stated, 'I am pleased to share that we continue to make considerable progress across our focused markets. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipelines, and focusing on resolving regulatory challenges.' For FY26, Cipla has guided for EBITDA margins between 23.5 per cent and 24.5 per cent. Growth will be driven by respiratory product launches in the US, new rollouts in India and emerging markets, and strong momentum in the GLP-1 segment, which is seen as a transformative opportunity. While US revenue forecasts remain conservative due to expected Lenalidomide erosion, the company is confident that its expanding pipeline will offset the impact. This quarter, Cipla's India business reported strong performance across all segments. In branded prescription, key therapies like respiratory, urology, cardiac, anti-diabetes, and anti-infectives outpaced market growth, with the chronic portfolio forming 61.5 per cent of sales. Trade generics saw robust growth, aided by strong execution, new product introductions (including entry into orthopaedics), and tech-led initiatives, with seven product launches during the quarter. In consumer health, anchor brands Nicotex, Omnigel, and Cipladine retained leadership in their categories. In North America, Cipla posted revenue of $226 million, driven by differentiated assets. Albuterol reached 19.5 per cent market share, while Lanreotide reached 21 per cent. Launches like nano paclitaxel vials and Nilotinib capsules are set to boost Cipla's oncology and complex generics presence. A strategic tie-up will also bring its first U.S. biosimilar to market in Q2 FY26. For Africa, the company delivered an 11 per cent YoY growth in USD terms, with private market growth. Cipla ranked number 3 overall in South Africa's private market, with its prescription business at number 2, driven by growth in key therapies, tender business, and new launches. In the emerging markets and Europe, the company's focused strategy yielded 8 per cent growth in USD terms, supported by momentum in both DTM and B2B segments, while maintaining stable margins. Cipla also reported a relatively higher research and development (R&D) spend this quarter at 6.2 per cent of revenue. The company sees its biggest growth opportunity in executing a strong pipeline of new product launches, particularly in the respiratory segment, with 3–4 launches lined up for the US and several more planned for emerging markets and India. Cipla is also continuing to actively invest in biosimilars and mRNA platforms, with a Centre of Excellence in Europe, capacity building at its Goa facility, and collaboration with Ethris. A biosimilar in supportive therapy is on track for launch in FY26. The company is also advancing early-stage work in CAR-T and cell/gene therapies, with ongoing evaluations and potential partnerships. Cipla holds a strong net cash position of Rs 10,800 crore and maintains a cautious, science-led M&A strategy, prioritising differentiated, patient-centric products over plain-vanilla brand acquisitions. Internal capital expenditure and R&D investments remain elevated to support long-term growth. From a risk perspective, potential US tariffs are not expected to materially impact generics, though branded products may face greater pressure. Regulatory scrutiny remains a key risk, particularly in manufacturing compliance. Cipla eyes Day 1 launch of GLP-1 drug in 2026 Cipla has identified the GLP-1 category—led by blockbuster drug Semaglutide—as its most significant therapeutic opportunity in the next five years. The company aims for a Day 1 launch after patents expire in mid-2026, using a mix of in-house and partner filings in key global markets. Calling the GLP-1 space 'transformational,' Cipla is adopting a dual filing strategy through both in-house development and external partnerships to ensure early market entry. 'We see the GLP-1 category, including Semaglutide, as one of the biggest therapy opportunities in the last five years,' said Umang Vohra, Managing Director and Global CEO of Cipla. 'Our approach is a mix of own and partner filings to ensure market presence from day one, especially in key markets.' In India, Cipla is working on an economically viable strategy not only for Semaglutide but for the entire GLP-1 portfolio, anticipating price erosion post-2026 but offset by volume growth. Cipla is also monitoring a recent Delhi High Court order restricting fixed-dose GLP-1 combinations but does not anticipate major disruptions for mono-variant GLP-1 therapies. Earlier, Dr. Reddy's Laboratories revealed plans to enter the GLP-1 space with Semaglutide across 87 countries starting in 2026.
News18
an hour ago
- News18
Irdai imposes Rs 3.39 cr penalty on Star Health Insurance
New Delhi, Jul 25 (PTI) Regulator Irdai on Friday said it has imposed a Rs 3.39 crore penalty on Star Health and Allied Insurance for various violations of Information & Cyber Security Guidelines. The Insurance Regulatory and Development Authority (Irdai) has also issued a warning to the insurer. 'Irdai…has imposed a penalty of Rs Three Crore Thirty-Nine Lakhs and a warning for various violations established under Irdai Information & Cyber Security Guidelines, 2023," the regulator said in its order on Star Health and Allied Insurance. Star Health Insurance has a strong multi-channel distribution network, with 913 offices, over 14,000 network hospitals, more than 7,75,000 licensed agents, and 17,000 employees. In 2024-25, Star Health's gross written premium stood at Rs 17,553 crore, with its net worth at Rs 8,668 crore. PTI NKD NKD BAL BAL Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Time of India
an hour ago
- Time of India
HAU scientists make landmark discovery in strawberry crown rot disease
1 2 Hisar: In a groundbreaking discovery, scientists at Chaudhary Charan Singh Haryana Agricultural University (CCSHAU), Hisar, identified 'colletotrichum nymphaeae' as the causal organism behind crown rot disease in strawberries, which is a major threat to fruit yield. This is the first-ever report of this pathogen causing crown rot in strawberries in India. University vice-chancellor Prof B R Kamboj highlighted the importance of early scientific interventions to manage emerging crop diseases and ensure the long-term sustainability of fruit production. He noted that the university's scientists are working actively to develop effective management strategies and expressed confidence in finding viable solutions soon. The research findings were accepted for publication in Physiological and Molecular Plant Pathology, a globally recognised journal published by Elsevier, with a NAAS rating of 8.8. The journal acknowledged this study as the first formal documentation of Colletotrichum nymphaeae as a crown rot pathogen in strawberries from India, marking a significant contribution to global plant pathology research. HAU's director of research, Rajbir Garg, said that Hisar has become one of the largest strawberry-producing clusters in North India, with around 700 acres under cultivation. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like No annual fees for life UnionBank Credit Card Apply Now Undo Strawberries grown in Saharwa village of Hisar are even reaching international markets. Inspired by Saharwa's success, farmers from nearby villages — Chanana, Harita, and Miran — have also taken up strawberry cultivation, helping transform the region into a high-value fruit farming hub. The foundation of the strawberry cluster in Hisar was laid in 1996 by HAU scientists. Since then, the region has seen steady growth in production despite ongoing biological challenges. Among these, crown rot disease has become a particularly serious concern, threatening both yield and profitability. Adesh Kumar, lead researcher of the study, said the research team is focused on understanding the disease outbreak and developing targeted strategies to reduce its impact. Their aim is to ensure the safety and sustainability of strawberry cultivation in the region. Contributing members of the research team include HAU scientists Anil Kumar Saini, Sushil Sharma, Rakesh Gehlot, Anil Kumar, Rakesh Kumar, K.C. Rajesh Kumar, Vikas Kumar Sharma, Romi Rawal, R.P.S. Dalal, and PhD scholar Shubham Saini. MSID:: 122906399 413 |
